| [Purpose]The subject of clinical efficacy to be compared to evaluate the efficacy of TCM Syndrome,clinical neurological deficits integral,functional disability score(mRS scale),plasma fibrinogen,blood lipids,blood sugar improvement and ischemic stroke recurrence rate,mortality rate,The incidence of adverse reactions,such as indicators to observe changes in Erigeron Shengmai Capsule on ischemic stroke secondary prevention efficacy,and its mechanism for patients to alleviate pain,improve clinical efficacy and prevention of cerebrovascular disease has important significance.[Method]Would be consistent with the inclusion criteria of patients with ischemic stroke of 56 cases,in accordance with the order entry group were randomly divided into two groups(treatment group,control group) of the 28 cases,a comparative study.A randomized,placebo-controlled,double-blind clinical study design.Oral treatment group Erigeron Shengmai Capsule(from Yunnan Valley Breviscapine Biology Medicine Co.,Ltd. Production:Drug lot number Z20026439),each piece costs 0.18g, each two,half an hour postprandial oral,2 times daily;the control group oral comfort agent capsule(Yunnan Valley Breviscapine Biology Medicine Co.,Ltd.production),each piece costs 0.18g,each two,half an hour postprandial oral, 2 times daily;two groups of Chinese and Western medicine on the basis of treatment with reference to relevant standards; these drugs were Continuous treatment for 3 months.Pre-treatment of two groups of gender,age,course of disease,basic diseases,basic information such as clinical score were compared by statistical treatment no significant difference(P＞0.05),note the two groups are comparable;after treatment according to clinical efficacy,TCM Syndrome Evaluation,plasma fibrinogen,blood lipids,as well as recurrence rate,mortality rate,incidence of adverse reactions,such as indicators for evaluation,statistical analysis,to evaluate Erigeron Shengmai Capsule on secondary prevention of ischemic stroke patients.[Results]1.Comparison of Clinical Efficacy:treatment group recovered eight cases,11 cases of significant progress, progress in 3 cases,no change in two cases,the total effective rate 85.71%;the treatment group recovered five cases,12 cases of significant improvement,2 cases of progressive,non-Change three cases,two cases of deterioration,the total effective rate 78.57%.By Ridit test P＜0.05,indicate efficacy of the treatment group significantly better than the control group. 2.Chinese medicine card period of five days integral comparison:Before two groups treat,the Chinese medicine card period of five days integral comparison,not remarkable difference(p＞0.05);After two groups treat,own Chinese medicine card period of five days integral comparison,has the remarkable difference(p＜0.05);After two groups treat, Chinese medicine card period of five days integral comparison, difference remarkable(p＜0.01).3.clinical nerve function damage degree integral comparison:Before the treatment group treats,the integral 12.28±5.82,after the treatment,integra18.67±5.35;Before the control group treats,the integral 11.75±6.74,after the treatment,integral 7.56±6.22.By paired t test,the treatment group after treatment than before treatment to improve the neurological deficit score differences were significant(P＜0.01),and inter-group difference after treatment also significantly(P＜0.05)4.Lipids,blood glucose changes:to improve the PT,PPT, TT,the treatment group before and after treatment significantly decreased(P＜0.01);control group,TT and Tch before and after treatment there was a significant difference (P＜0.05),PTand PPT before and after treatment there was no significant difference(P＞0.05).Treatment group and control group after treatment than before treatment FBG has significantly decreased(P＜0.05),between the two groups after treatment FBG value of the difference was not significant.[Conclusion]The results show that the application of Yiqi Yangyin, Huoxue Jiannao efficacy Erigeron Shengmai capsule can be adjusted in patients with ischemic stroke recovery of the blood lipid,lower plasma fibrinogen levels,lower blood viscosity, can effectively improve the clinical symptoms,and to prevent the recurrence of stroke there is a certain degree of efficacy. However,because of smaller sample size,observed a shorter cycle,but also to be one step into a strict program design, expanding the sample size,to carry out large-scale, multi-center clinical trial for pharmaceutical intervention in secondary prevention of ischemic stroke based on the provision of evidence-based medicine.
|
PDF Full Text Request